- Poster presentation
- Open Access
Interscan reproducibility of cardiovascular magnetic resonance myocardial perfusion reserve index in women with suspected coronary microvascular dysfunction and no obstructive coronary artery disease
© AlBadri et al. 2016
- Published: 27 January 2016
- Coronary Artery Disease
- Cardiovascular Magnetic Resonance
- Obstructive Coronary Artery Disease
- Rate Pressure Product
- Interobserver Reproducibility
Cardiovascular magnetic resonance (CMR) myocardial perfusion reserve index (MPRI) has recently shown promise for detecting coronary microvascular dysfunction (CMD) in women with signs and symptoms of ischemia and no obstructive coronary artery disease (CAD). Prior CMR studies in CAD populations and in healthy volunteers have shown good intra and interobserver reproducibility for MPRI. However, interscan reproducibility is more variable. If MPRI is to be considered useful for the detection of CMD in women, the interscan reproducibility in this population must also be understood, such that proposed MPRI cut-off thresholds can be appropriately adjusted. Therefore, the aim of this study was to determine the interscan reproducibility of MPRI in women with suspected CMD.
Rest/stress perfusion CMR was performed at 1.5T using a standardized protocol in 27 women with signs and symptoms of ischemia and no obstructive CAD on two separate days. Cardiovascular medications were held for 24-48 hours before each scan. The same pharmacological stress agent (adenosine/regadenoson) was used for both scans. MPRI was calculated from time-intensity curves of the whole myocardium and blood pool at stress and rest (CAAS MRV 3.3, Pie Medical Imaging B.V., Netherlands). One experienced observer, blinded to clinical data, performed all measurements. Intra-class correlation coefficients (ICC), coefficient of variation (CoV), and Bland-Altman plots were determined.
Interscan reproducibility of CMR-derived MPRI in women with suspected CMD was only modest, with relatively wide limits of agreement. This variability is very similar to that seen in other populations and means that some caution must be exercised when using absolute MPRI cut-offs in isolation for the diagnosis of CMD, or repeated measures of MPRI to track response to therapy. The combination of clinical factors and symptom review with MPRI is therefore likely to be the optimal strategy, rather than its use in isolation.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.